4-[2-(4-tert-butoxycarbonylaminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yloxy]piperidine-1-carboxylic acid tert-butyl ester | 842144-00-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-[2-(4-tert-butoxycarbonylaminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yloxy]piperidine-1-carboxylic acid tert-butyl ester
• 英文别名: 4-[2-(4-tert-Butoxycarbonylamino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yloxy]-piperidine-1-carboxylic acid tert-butyl ester；tert-butyl 4-[1-ethyl-2-[4-[(2-methylpropan-2-yl)oxycarbonylamino]-1,2,5-oxadiazol-3-yl]imidazo[4,5-c]pyridin-7-yl]oxypiperidine-1-carboxylate
• CAS: 842144-00-7
• 化学式: C₂₅H₃₅N₇O₆
• 分子量: 529.596
• InChiKey: RNPRRSYEXSQTAK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  38
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  147
• 氢给体数：
  1
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  4-[2-(4-tert-butoxycarbonylaminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yloxy]piperidine-1-carboxylic acid tert-butyl ester 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 0.67h， 以97%的产率得到4-[1-ethyl-7-(piperidin-4-yloxy)-1H-imidazo[4,5-c]pyridine-2-yl]-furazan-3-ylamine trifluoroacetate
  参考文献：
  名称：

  [EN] INHIBITORS OF Akt ACTIVITY
  [FR] INHIBITEURS DE L'ACTIVITE DE AKT

  摘要：

  发明了新型的1H-咪唑[4,5-c]吡啶-2-基化合物，这些化合物用作蛋白激酶B活性的抑制剂，并用于治疗癌症和关节炎。

  公开号：

  WO2005011700A1
• 作为产物：
  描述：

  [4-(1-ethyl-7-hydroxy-1H-imidazo[4,5-c]pyridin-2-yl)furazan-3-yl]carbamic acid tert-butyl ester 、 N-Boc-4-羟基哌啶 在 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 二氯甲烷 为溶剂， 反应 1.67h， 以43%的产率得到4-[2-(4-tert-butoxycarbonylaminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yloxy]piperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  [EN] INHIBITORS OF Akt ACTIVITY
  [FR] INHIBITEURS DE L'ACTIVITE DE AKT

  摘要：

  发明了新型的1H-咪唑[4,5-c]吡啶-2-基化合物，这些化合物用作蛋白激酶B活性的抑制剂，并用于治疗癌症和关节炎。

  公开号：

  WO2005011700A1

文献信息

• [EN] CANCER TREATMENT METHOD<br/>[FR] METHODE DE TRAITEMENT DU CANCER
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2005046678A1

  公开（公告）日：2005-05-26

  The present invention relates to a method of treating cancer in a mammal and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering an erb family inhibitor and a PI3K and/or Akt inhibitor to a mammal suffering from a cancer.

  本发明涉及一种治疗哺乳动物癌症的方法以及在这种治疗中有用的药物组合。具体而言，该方法涉及一种癌症治疗方法，其中向患有癌症的哺乳动物施用一种erb家族抑制剂和一种PI3K和/或Akt抑制剂。
• Inhibitors of Akt Activity
  申请人：Heerding Dirk A.

  公开号：US20080255143A1

  公开（公告）日：2008-10-16

  Invented are novel 1H-imidazo[4,5-c]pyridin-2-yl compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.

  发明了新型的1H-咪唑[4,5-c]吡啶-2-基化合物，这些化合物可用作蛋白激酶B活性抑制剂，并用于癌症和关节炎的治疗。
• Cancer treatment method
  申请人：Dev Kumar Inderjit

  公开号：US20070161665A1

  公开（公告）日：2007-07-12

  The present invention relates to a method of treating cancer in a mammal and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering an erb family inhibitor and a PI3K and/or Akt inhibitor to a mammal suffering from cancer.

  本发明涉及一种治疗哺乳动物癌症的方法，以及在这种治疗中有用的药物组合。具体而言，该方法涉及一种癌症治疗方法，包括向患有癌症的哺乳动物施用erb家族抑制剂和PI3K和/或Akt抑制剂。
• [EN] INHIBITORS OF Akt ACTIVITY<br/>[FR] INHIBITEURS DE L'ACTIVITE DE AKT
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2005011700A1

  公开（公告）日：2005-02-10

  Invented are novel 1 H-imidazo[4,5-c]pyridin-2-yI compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.

  发明了新型的1H-咪唑[4,5-c]吡啶-2-基化合物，这些化合物用作蛋白激酶B活性的抑制剂，并用于治疗癌症和关节炎。
• Identification of 4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3<i>S</i>)-3-piperidinylmethyl]oxy}-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a Novel Inhibitor of AKT Kinase
  作者：Dirk A. Heerding、Nelson Rhodes、Jack D. Leber、Tammy J. Clark、Richard M. Keenan、Louis V. Lafrance、Mei Li、Igor G. Safonov、Dennis T. Takata、Joseph W. Venslavsky、Dennis S. Yamashita、Anthony E. Choudhry、Robert A. Copeland、Zhihong Lai、Michael D. Schaber、Peter J. Tummino、Susan L. Strum、Edgar R. Wood、Derek R. Duckett、Derek Eberwein、Victoria B. Knick、Timothy J. Lansing、Randy T. McConnell、ShuYun Zhang、Elisabeth A. Minthorn、Nestor O. Concha、Gregory L. Warren、Rakesh Kumar

  DOI：10.1021/jm8004527

  日期：2008.9.25

  Overexpression of AKT has an antiapoptotic effect in many cell types, and expression of dominant negative AKT blocks the ability of a variety of growth factors to promote survival. Therefore, inhibitors of AKT kinase activity might be useful as monotherapy for the treatment of tumors with activated AKT. Herein, we describe our lead optimization studies culminating in the discovery of compound 3g (GSK690693). Compound 3g is a novel ATP competitive, pan-AKT kinase inhibitor with IC 50 values of 2, 13, and 9 nM against AKT1, 2, and 3, respectively. An X-ray cocrystal structure was solved with 3g and the kinase domain of AKT2, confirming that 3g bound in the ATP binding pocket. Compound 3g potently inhibits intracellular AKT activity as measured by the inhibition of the phosphorylation levels of GSK3beta. Intraperitoneal administration of 3g in immunocompromised mice results in the inhibition of GSK3beta phosphorylation and tumor growth in human breast carcinoma (BT474) xenografts.